BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs
BIVI•BIV201 program status
BIV201, a continuous IV terlipressin formulation for ascites, was positioned as Phase 3-ready with an FDA-agreed single registrational trial design.
Sales potential cited in materials
Pipeline materials cited annual U.S. sales potential estimates of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, and $1.6 billion for ascites.
Parkinson’s and Long COVID endpoints
Parkinson’s readouts emphasized EPNIC-15, a composite spanning MDS-UPDRS Parts I-III and PDSS-2 to capture motor and non-motor change.
Corporate presentation highlights pipeline programs
BioVie highlighted bezisterim, an oral, blood-brain barrier-penetrating small molecule targeting TNFα-driven inflammation across Parkinson’s, Long COVID, and Alzheimer’s.
Topline data are expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease, with Long COVID Phase 2 results also slated for 3Q 2026.
